CONCORD

Concord Drugs Share Price

 

 

Start SIP in CONCORD

Start SIP

Performance

  • Low
  • ₹0
  • High
  • ₹0
  • 52 Week Low
  • ₹0
  • 52 Week High
  • ₹0
  • Open Price₹0
  • Previous Close₹0
  • Volume
  • 50 DMA₹80.05
  • 100 DMA₹73.02
  • 200 DMA₹62.49

Investment Returns

  • Over 1 Month + 1.2%
  • Over 3 Month + 20.66%
  • Over 6 Month + 27.71%
  • Over 1 Year + 123.37%

Smart Investing Starts Here Start SIP with Concord Drugs for Steady Growth!

Invest Now

Concord Drugs Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

Concord Drugs Financials

Concord Drugs Technicals

EMA & SMA

Current Price
₹82.00
-1.06 (-1.28%)
  • Bearish Moving Average 0
  • Bullish Moving Average 0
  • 20 Day
  • ₹83.73
  • 50 Day
  • ₹80.05
  • 100 Day
  • ₹73.02
  • 200 Day
  • ₹62.49

Resistance and Support

81.09 Pivot Speed
  • R3 88.02
  • R2 85.95
  • R1 83.16
  • S1 78.30
  • S2 76.23
  • S3 73.44

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Concord Biotech Limited is an R&D-driven biopharma company with two API units and one formulation unit in Gujarat, India. The company supplies APIs and finished formulations across 70+ countries, including the USA, Europe, Japan, and India.

Concord Biotech Ltd has an operating revenue of Rs. 1,125.15 Cr. on a trailing 12-month basis. An annual revenue growth of 18% is outstanding, Pre-tax margin of 41% is great, ROE of 20% is exceptional. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 43 which is a POOR score indicating inconsistency in earnings, a RS Rating of 18 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B- which is evident from recent demand for the stock, Group Rank of 91 indicates it belongs to a poor industry group of Medical-Biomed/Biotech and a Master Score of D is close to being the worst. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Concord Drugs Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-11-13 Quarterly Results
2025-08-08 Quarterly Results
2025-07-03 Preferential issue of shares
2025-06-27 Preferential Issue of shares & Others Inter-alia, to consider 1. the date, time, and venue for convening an ExtraOrdinary General Meeting of the Company. 2. Other business matters.
2025-05-23 Audited Results

Concord Drugs F&O

Concord Drugs Shareholding Pattern

44.08%
4.53%
3.9%
8.03%
7.77%
31.69%

About Concord Drugs

  • NSE Symbol
  • CONCORD
  • BSE Symbol
  • 538965
  • Chairman & Managing Director
  • Mr. Sudhir Vaid
  • ISIN
  • INE858L01010

Similar Stocks to Concord Drugs

Concord Drugs FAQs

Concord Drugs share price is ₹82 As on 13 January, 2026 | 06:41

The Market Cap of Concord Drugs is ₹108 Cr As on 13 January, 2026 | 06:41

The P/E ratio of Concord Drugs is 187.7 As on 13 January, 2026 | 06:41

The PB ratio of Concord Drugs is 2.9 As on 13 January, 2026 | 06:41

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23